Briumvi significantly outperformed Aubagio at reducing disease activity in people with highly active relapsing forms of MS, a ...

Reduced daytime physical activity, as measured with wearable trackers, is tied to increased risk for multiple sclerosis progression and brain atrophy, new research shows.

A longtime couple who coincidentally both have a life-altering disease consider themselves “lucky” to have each other. They ...

Guest writer Reché Jones says it took her years to be diagnosed with relapsing-remitting MS. Now she plans to "keep moving." ...

In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...

Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 –– Broad ...

Immunic receives European patent protecting relevant dosing regimens for vidofludimus calcium: New York Thursday, March 12, 2026, 12:00 Hrs [IST] Immunic, Inc., a late-stage biote ...

Persistence of high EBNA-1 titers across longitudinal samples was characteristic of MS, whereas MOGAD and NMOSD generally exhibited titer attenuation during follow-up. High-level EBNA-1 positivity in ...

Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Extavia Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The ...

Dr Olivia Wills secures MS Australia grant to investigate whether lifestyle-based weight loss alters mouth bacteria and improves health outcomes ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), ...

SAN DIEGO, March 13, 2026--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for ...